111 Capital’s United Therapeutics UTHR Stock Holding History

111 Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$487K	Buy	+898	New	+$506K	0.08%	245
2025 Q4	–	Sell	-720	Closed	-$302K	–	541
2025 Q3	$302K	Buy	+720	New	+$242K	0.06%	319

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

111 Capital's UTHR Position: Q2 2026 in Review

111 Capital opened a new position in United Therapeutics (UTHR) in Q2 2026: 898 shares worth $487K. The stake represents 0.08% of the portfolio and ranks #245 among its holdings. This is a return to the name: 111 Capital previously reported a position in UTHR as recently as Q3 2025.

111 Capital first reported a position in UTHR in Q3 2025 and has held it in 2 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

111 Capital held 898 shares of United Therapeutics worth $487K as of Q2 2026.
United Therapeutics was a new 111 Capital position in Q2 2026.
United Therapeutics made up 0.08% of 111 Capital's portfolio in Q2 2026, its #245 holding.
111 Capital first reported a position in United Therapeutics in Q3 2025 and has held it in 2 quarters since.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.